Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 1999

View Archived Issues

Roche and Genentech relationship unaffected by public offering; Genentech provides Q3 update

Licensing opportunity from NIH: aspartic HIV protease inhibitors

Atlantic reports analgesic effects of CT-3 in mouse model

Teva announces possible acquisition of Novopharm

Orphan Medical completes licensing agreement with Pierre Fabre

Vasogen cleared to proceed with psoriasis clinical trial

Expanded agreement between Vertex and HMR receives Hart-Scott-Rodino clearance

Centocor submits sBLA to FDA for Remicade as treatment of rheumatoid arthritis

StressGen completes clinical trial with lead product during third quarter

Roche patents new compounds with MDM2-antagonist activity useful for treatment of tumors

Galderma describes new apoptosis-inducing antitumor agents

Novel prostaglandin analogues useful for bone disorders, glaucoma

Retinoid receptor-active compounds from Galderma for skin disorders

Neuroprotective fullerene derivatives designed by Aventis R&T

EASD highlights: novel aldose reductase inhibitor effective in model of diabetic neuropathy

Wilex and Ludwig Institute collaborate on clinical development of G250

Sonus's lead ultrasound contrast agent moves closer to commercialization

Chemosensitizing agent from Procept enters phase II for multiple myeloma

Phase II clinical trials initiated for humanized anti-CD3 antibody developed at PDL

First prescription drug approved in U.K. for severe PMS

Proof-of-concept trial begins for Vivus's oral PE compounds

The antidementia drug donepezil may also be beneficial in Lewy body dementia

Neuroprotective effects demonstrated for mglu receptor agonists in vitro and in vivo

Increasing NO levels in blood as novel strategy for sickle cell disease

Xyrem headed for NDA submission in a year

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...